Key result
PPCM requires standard HF therapy with special provisions for pregnant and lactating women.
Peripartum cardiomyopathy is a potentially devastating disease requiring a high index of suspicion for diagnosis and standard heart failure treatment with special provisions for pregnant and lactating women.
Answers are grounded in this paper and cite their sources.
Emphasizes tailored HF management for peripartum cardiomyopathy during pregnancy and lactation; leaves open etiology and targeted therapies.
Peripartum cardiomyopathy (PPCM) is a potentially devastating disease that affects women during the last months of pregnancy or the first months after delivery. The aetiology and pathogenesis of this disease remain unclear, but oxidative stress and the generation of a cardiotoxic fragment of prolactin may play key roles. Diagnosing PPCM remains a challenge, as symptoms may mimic those women experience during normal pregnancy and the peripartum period. A high index of suspicion is thus necessary to make the diagnosis. Patients with PPCM have a varied clinical course, as some patients achieve full recovery while others progress to end-stage heart failure and even death. Standard heart failure treatment is indicated, although special provisions are necessary in pregnant and lactating women. Additional research into the pathophysiology of this disease, including possible genetic contributions, may lead to novel treatment strategies that can improve outcomes.
No takes yet. Share an insight, caveat, or question.
Blauwet et al. (2011) conducted a review in Peripartum cardiomyopathy. Peripartum cardiomyopathy is a challenging disease with unclear etiology and varied clinical course that requires standard heart failure treatment with special provisions for pregnant and lactating women.
Synapse has enriched 10 related papers. Consider them for comparative context: